Comparable stake leader
BlackRock, Inc.
SEC ownership of ANAVEX LIFE SCIENCES CORP.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001314052.
Disclosed value leader
BlackRock, Inc.
Comparable rows
0/50
Latest evidence
31 Mar 2026
- Public ticker
- AVXL on Nasdaq
- Parsed ownership sources
- 13F and 3/4/5
- Largest SEC-reported holder
- BlackRock, Inc.
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001314052
- Issuer location
- New York, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ANAVEX LIFE SCIENCES CORP. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
0/50
Latest evidence
31 Mar 2026
13F
3/4/5
Highest disclosed value: $23,361,527
50 rows are not safely comparable across share classes.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. has the largest disclosed position value at $23.36M.
0 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Disclosed position value
Top 5
BlackRock, Inc.
$23.36M
Christopher U. Missling
$14.47M
STATE STREET CORP
$13.85M
VANGUARD CAPITAL MANAGEMENT LLC
$11.86M
TWO SIGMA INVESTMENTS, LP
$9.97M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
Company
|
—
class O/S missing
|
$23,361,527
7,609,618 shares
|
— | 31 Mar 2026 |
| Christopher U. Missling |
3/4/5
President and CEO, Director
|
—
mixed-class rows
|
$14,467,380
1,635,165 shares
mixed-class rows
|
— | 06 Jan 2026 |
| STATE STREET CORP |
13F
Company
|
—
class O/S missing
|
$13,851,926
4,512,028 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
class O/S missing
|
$11,862,327
3,863,950 shares
|
— | 31 Mar 2026 |
| TWO SIGMA INVESTMENTS, LP |
13F
Company
|
—
class O/S missing
|
$9,971,016
3,247,888 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
class O/S missing
|
$6,719,665
2,188,275 shares
|
— | 31 Mar 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
Company
|
—
class O/S missing
|
$3,056,685
995,663 shares
|
— | 31 Mar 2026 |
| Summit Financial, LLC |
13F
Company
|
—
class O/S missing
|
$2,887,197
940,455 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to ANAVEX LIFE SCIENCES CORP.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Christopher U. Missling
Net 12M change
$0
Latest report
04 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Christopher U. Missling | President and CEO, Director | $14,467,380 | Mixed | 06 Jan 2026 | ||
| Steffen Thomas | Director | $338,295 | Mixed | 05 Jun 2025 | ||
| Peter D.o. Donhauser | Director | $18,200 | Filing P/S | 31 Mar 2025 | ||
| Elliot Favus | Director | Mixed | 21 May 2021 | |||
| Sandra Boenisch | PFO & Treasurer | Mixed | 06 Jan 2026 | |||
| Claus Vander Velden | Director | Mixed | 31 Mar 2025 | |||
| Axel Paeger | Director | Mixed | 23 Feb 2026 | |||
| Terrie Kellmeyer | Interim CEO | Mixed | 04 May 2026 | |||
| Jiong Ma | Director | Mixed | 31 Mar 2025 | |||
| Athanasios Skarpelos | Director | Mixed | 31 Mar 2025 |
Recent insider transactions for ANAVEX LIFE SCIENCES CORP.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Christopher U. Missling | AVXL | Stock Option (Right to Buy) | Award | 125,000 | 125,000 | 06 Jan 2026 | Direct | |||
| Sandra Boenisch | AVXL | Stock Option (Right to Buy) | Award | 12,500 | 12,500 | 06 Jan 2026 | Direct | |||
| Sandra Boenisch | AVXL | Stock Option (Right to Buy) | Award | 100% | 12,500 | 25,000 | 02 Oct 2025 | Direct | ||
| Christopher U. Missling | AVXL | Stock Option (Right to Buy) | Award | 100% | 125,000 | 250,000 | 02 Oct 2025 | Direct | ||
| Christopher U. Missling | AVXL | Common Stock | Tax liability | -8.76% | -145,048 | 1,510,165 | 11 Sep 2025 | Direct | ||
| Christopher U. Missling | AVXL | Common Stock | Options Exercise | 12.8% | 187,500 | 1,655,213 | 11 Sep 2025 | Direct | ||
| Christopher U. Missling | AVXL | Stock Option (Right to Buy) | Options Exercise | -100% | -187,500 | 0 | 11 Sep 2025 | Direct | ||
| Sandra Boenisch | AVXL | Stock Option (Right to Buy) | Award | 12,500 | 12,500 | 20 Aug 2025 | Direct | |||
| Christopher U. Missling | AVXL | Stock Option (Right to Buy) | Award | 125,000 | 125,000 | 20 Aug 2025 | Direct | |||
| Steffen Thomas | AVXL | Common stock | Tax liability | -20.6% | -11,349 | 43,651 | 05 Jun 2025 | Direct | ||
| Steffen Thomas | AVXL | Common stock | Options Exercise | 1000% | 50,000 | 55,000 | 05 Jun 2025 | Direct | ||
| Steffen Thomas | AVXL | Stock Option (Right to Buy) | Options Exercise | -100% | -50,000 | 0 | 05 Jun 2025 | Direct |
* marks a reported price that did not pass the local price check.